Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccinationJanžič, Urška (Avtor) Bidovec, Urška (Avtor) Mohorčič, Katja (Avtor) Mrak, Loredana (Avtor) Fokter Dovnik, Nina (Avtor) Ivanović, Marija (Avtor) Ravnik, Maja (Avtor) Čakš, Marina (Avtor) Škof, Erik (Avtor) Debeljak, Jerneja (Avtor) Korošec, Peter (Avtor) Rijavec, Matija (Avtor) onkološko zdravljenjeimunogenostosnovno cepljenje mRNAčvrsti tumorjianticancer treatmentimmunogenicitymRNA-based vaccinationsolid cancerBackground: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and second doses and 3 months after a complete primary course of vaccination. Results were compared with healthy controls. Results: Of 112 patients, the seroconversion rate was 96%. A significant reduction in antibody levels was observed 3 months after vaccination in patients receiving immune checkpoint inhibitors versus control participants (p < 0.001). Adverse events were mostly mild. Conclusion: Immunogenicity after mRNA-based vaccine in cancer patients is adequate but influenced by the type of anticancer therapy. Antibody levels decline after 3 months, and thus a third vaccination is warranted.Future Medicine20222022-06-24 13:02:16Neznano15227UDK: 616-006ISSN pri članku: 1479-6694DOI: 10.2217/fon-2022-0148COBISS_ID: 111378179sl(C) 2022 The Authors